Keytruda Inj and Opdivo Inj approved promptly for off-label use

Published: 2017-09-21 16:28:00
Updated: 2017-09-21 13:30:00

The Health Insurance Review & Assessment Service(President Seung-Taek Kim, HIRA) decided to approve off-label uses of Keytruda Inj(generic name: pembrolizumab) and Opdivo Inj(generic name: nivolumab), immune checkpoint inhibitors applied to medical institutes at the Multidisciplinary Committee, a...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.